文献速递药物相互作用特殊人群用药

肝移植后粉碎索磷布韦/维帕他韦与大剂量泮托拉唑联用实现丙肝病毒清除

Hepatitis C viral clearance with coadministration of crushed sofosbuvir/velpatasvir and high-dose pantoprazole after liver transplantation.
PubMed 文献 · Am J Health Syst Pharm · 2022-01-01

一例31岁丙肝阴性女性接受丙肝NAT阳性供肝后,因黏膜感染、消化道出血、坏死性胰腺炎等需脂质体两性霉素B和泮托拉唑80mg每日两次,经鼻胃管给予粉碎索磷布韦/维帕他韦,4周内丙肝病毒清除,但12周持续病毒学应答前死亡。

要点

  • 粉碎索磷布韦/维帕他韦经鼻胃管给药可用于肝移植后多重吸收顾虑患者。
  • 与泮托拉唑80mg每日两次联用下仍观察到4周内丙肝病毒清除。
  • 该患者因死亡未能评估12周持续病毒学应答。

核心结论

  • 肝移植患者存在多重吸收顾虑时,粉碎索磷布韦/维帕他韦经鼻胃管给药仍可实现丙肝病毒清除。

研究设计与样本

  • 病例报告:一例31岁丙肝阴性女性接受丙肝NAT阳性供肝移植。

主要发现

  • 治疗后4周内观察到丙肝病毒清除。
  • 患者因死亡未评估12周持续病毒学应答。

关键数值与推荐

  • 粉碎索磷布韦/维帕他韦与30mL水混合经鼻胃管每日给药。
  • 泮托拉唑剂量为80mg每日两次。

临床怎么用

  • 肝移植后存在吸收顾虑且需大剂量质子泵抑制剂时,可考虑粉碎索磷布韦/维帕他韦经鼻胃管给药并每周监测病毒载量。

局限性

  • 单例病例报告,证据等级有限。
  • 患者死亡未获得12周持续病毒学应答数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Direct-acting antivirals (DAAs) allow for successful transplantation of livers from hepatitis C nucleic acid test (NAT)-positive donors to negative recipients. However, limited data exist to support crushing DAAs in patients with multiple absorption concerns or significant drug interactions. SUMMARY: Crushed sofosbuvir/velpatasvir has been successfully used in nontransplant patients with dysphagia, but data in transplant patients with absorption concerns are limited. A 31-year-old hepatitis C-negative female underwent liver transplantation from a hepatitis C NAT-positive donor. Her postoperative course was complicated by a mucormycosis infection, gastrointestinal bleed, and necrotizing pancreatitis requiring treatment with liposomal amphotericin B and pantoprazole 80 mg twice daily. Surgical interventions included an above-the-knee amputation and ileostomy. Hepatitis C treatment was initially delayed because of concern for reduced absorption with crushed DAA administration through the nasogastric (NG) tube, high ileostomy output, gastrointestinal bleed, pancreatitis, and a known drug interaction with pantoprazole. One month after transplantation, the patient's bilirubin level remained elevated and hepatitis C treatment was initiated with sofosbuvir/velpatasvir. Crushed sofosbuvir/velpatasvir was mixed with 30 mL of water and administered through the NG tube daily. Hepatitis C viral loads were obtained weekly during treatment to monitor efficacy. Although the patient died before evaluation of sustained virological response at 12 weeks, hepatitis C viral clearance was observed within 4 weeks of initiating treatment. CONCLUSION: A liver transplant patient exhibited viral clearance of hepatitis C following administration of crushed sofosbuvir/velpatasvir in the setting of multiple absorption concerns.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Pluckrose DM, Szczepanik A, Bova SE, et al. Hepatitis C viral clearance with coadministration of crushed sofosbuvir/velpatasvir and high-dose pantoprazole after liver transplantation. Am J Health Syst Pharm. 2022. PMID: 35675479. doi:10.1093/ajhp/zxac153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。